Stoke Therapeutics financials
$25.88+1.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — | — | — |
| Gross profit | $184.4M | $36.6M | $8.8M | $12.4M | — | — | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M | -$53.0M | -$35.7M |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M | -$52.2M | -$32.3M |
| Net margin | −3.7% | −243.4% | −1192.5% | −814.7% | — | — | — |
| Diluted EPS | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | $-1.56 | $-1.80 |
| EBITDA | -$18.8M | -$99.2M | -$112.3M | -$102.8M | -$83.8M | -$51.1M | -$35.2M |
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M | -$42.2M | -$31.1M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M | -$43.3M | -$32.7M |
| Diluted shares | 59.2M | 54.0M | 44.0M | 38.9M | 36.7M | 33.5M | 18.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.2M | $128.0M | $191.4M | $113.6M | $144.9M | $287.3M |
| Short-term investments | $200.4M | $88.9M | $10.0M | $116.0M | $74.9M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M | $297.9M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M | $11.8M |
| Shareholders' equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M | $286.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology